Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available.

Dr. Breelyn Wilky discusses some of the most recent advancements in GIST treatment, as well as touched on the role of ...

A young university student whose repeated symptoms of stomachache, nausea, vomiting, and weight loss were dismissed by ...

Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Deciphera Pharmaceuticals, LLC for QINLOCK® (ripretinib), which ...

There were no cases of HER2 positivity among patients with gliomas, sarcomas, small cell lung cancer, gastrointestinal stromal tumors, thyroid carcinoma, uterine sarcoma, thymic carcinoma, and Merkel ...

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

Total 497 GIST patients were involved in present study, with a median age of 60 years (range 23–90) and 55.9% was male. Stomach and small bowel were the most common sites of primary disease (59. ...

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) ...

Human papillomavirus (HPV) can drive tumor development in some rare sinonasal squamous cell carcinomas (SNSCCs), according to a new comprehensive study of these tumors from investigators at the ...

Rare Mutation Found in Solid Tumors At the time, they found a few instances of a separate XPO1 mutation linked to colorectal and endometrial cancers, dubbed XPO1R749Q.

BUFFALO, NY — June 13, 2025 — A new case report was published in Volume 12 of Oncoscience on May 22, 2025, titled “A rare case: Pure Sertoli cell tumor uncovered in atrophic ovary during ...